Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, randomized, double-blind, placebo-controlled, multicenter proof-of-concept study evaluating efficacy and safety of rilzabrutinib in adult patients with moderate to severe atopic dermatitis who are inadequate responders or intolerant to topical corticosteroids

    Summary
    EudraCT number
    2021-001704-15
    Trial protocol
    DE   NL   CZ  
    Global end of trial date
    23 Jun 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    04 Jul 2024
    First version publication date
    04 Jul 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ACT17207
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT05018806
    WHO universal trial number (UTN)
    U1111-1261-7565
    Sponsors
    Sponsor organisation name
    Sanofi aventis recherche & développement
    Sponsor organisation address
    82 Avenue Raspail, Gentilly, France, 94250
    Public contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Scientific contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    21 Jul 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    23 Jun 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To assess the efficacy of rilzabrutinib in participants with atopic dermatitis (AD).
    Protection of trial subjects
    Participants were fully informed of all pertinent aspects of clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the participant and considering the local culture. During the course of the trail, participants were provided with individual participant cards indicating the nature of the trial the participant is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 Sep 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Canada: 23
    Country: Number of subjects enrolled
    Chile: 25
    Country: Number of subjects enrolled
    Czechia: 33
    Country: Number of subjects enrolled
    Germany: 5
    Country: Number of subjects enrolled
    Netherlands: 1
    Country: Number of subjects enrolled
    Poland: 11
    Country: Number of subjects enrolled
    United States: 26
    Worldwide total number of subjects
    124
    EEA total number of subjects
    50
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    119
    From 65 to 84 years
    5
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 31 centers in 7 countries. 61 participants in twice a day(BID) cohort and 106 participants in three times a day(TID) cohort were screened from 09 September 2021 to 24 February 2023, of which 16 in BID cohort and 27 in TID cohort were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

    Pre-assignment
    Screening details
    A total of 45 participants in BID cohort and 79 participants in TID cohort were randomized in a ratio of 3:2 to receive either rilzabrutinib or matching placebo on Day 1 in the BID and TID cohorts, respectively.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Carer

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    BID cohort: Placebo
    Arm description
    Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo matched to rilzabrutinib was available as tablets (modified-capsule shaped tablets/caplets) and was administered orally BID from Day 1 up to Week 16.

    Arm title
    BID cohort: Rilzabrutinib 400 mg BID
    Arm description
    Participants received rilzabrutinib 400 milligrams (mg) orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).
    Arm type
    Experimental

    Investigational medicinal product name
    Rilzabrutinib
    Investigational medicinal product code
    Other name
    SAR444671, PRN1008
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Rilzabrutinib was supplied as 400 mg tablets (modified-capsule shaped tablets/caplets) and was administered orally BID from Day 1 up to Week 16.

    Arm title
    TID cohort: Placebo
    Arm description
    Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Placebo matched to rilzabrutinib was available as tablets (modified-capsule shaped tablets/caplets) and was administered orally TID from Day 1 up to Week 16.

    Arm title
    TID cohort: Rilzabrutinib 400 mg TID
    Arm description
    Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).
    Arm type
    Experimental

    Investigational medicinal product name
    Rilzabrutinib
    Investigational medicinal product code
    Other name
    SAR444671, PRN1008
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Rilzabrutinib was supplied as 400 mg tablets (modified-capsule shaped tablets/caplets) and was administered orally TID from Day 1 up to Week 16.

    Number of subjects in period 1
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Started
    18
    27
    31
    48
    Completed
    14
    23
    26
    31
    Not completed
    4
    4
    5
    17
         Consent withdrawn by subject
    3
    3
    3
    10
         Adverse event: Not related to COVID-19
    1
    1
    2
    7

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    BID cohort: Placebo
    Reporting group description
    Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Reporting group title
    BID cohort: Rilzabrutinib 400 mg BID
    Reporting group description
    Participants received rilzabrutinib 400 milligrams (mg) orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Reporting group title
    TID cohort: Placebo
    Reporting group description
    Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Reporting group title
    TID cohort: Rilzabrutinib 400 mg TID
    Reporting group description
    Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Reporting group values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID Total
    Number of subjects
    18 27 31 48 124
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    18 25 29 47 119
        From 65-84 years
    0 2 2 1 5
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    33.9 ( 13.0 ) 38.3 ( 16.1 ) 33.1 ( 12.4 ) 36.1 ( 14.1 ) -
    Sex: Female, Male
    Units: Participants
        Female
    10 15 15 31 71
        Male
    8 12 16 17 53
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0 0 0 0
        Asian
    2 2 4 6 14
        Native Hawaiian or Other Pacific Islander
    0 0 0 0 0
        Black or African American
    0 1 2 4 7
        White
    16 23 25 38 102
        More than one race
    0 1 0 0 1
        Unknown or Not Reported
    0 0 0 0 0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    BID cohort: Placebo
    Reporting group description
    Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Reporting group title
    BID cohort: Rilzabrutinib 400 mg BID
    Reporting group description
    Participants received rilzabrutinib 400 milligrams (mg) orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Reporting group title
    TID cohort: Placebo
    Reporting group description
    Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Reporting group title
    TID cohort: Rilzabrutinib 400 mg TID
    Reporting group description
    Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Primary: Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score

    Close Top of page
    End point title
    Percent Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score
    End point description
    EASI index is validated investigator-administered scoring system to measure severity of clinical signs in atopic dermatitis(AD). Four AD disease characteristics(erythema, thickness[induration, papulation, edema],scratching[excoriation],and lichenification) were each assessed for severity by investigator or designee on scale of "0"(absent) through "3(severe).In addition, area of AD involvement were assessed as percentage by body area of head,trunk,upper limbs,and lower limbs,and converted to score of 0 to 6. 0: 0% of body surface area(BSA) involvement with AD;1:1-9%;2: 10-29%;2:30-49%;4: 50-69%;5: 70-89% and 6: 90-100%.Total score=0(minimum) to 72(maximum);higher scores=greater severity of AD.Baseline=Day 1 assessment value. Intent-to-treat(ITT) population:all randomized participants analyzed according to intervention group allocated by randomization regardless of whether intervention was received or not.Only those participants with data collected at specified timepoints are reported.
    End point type
    Primary
    End point timeframe
    Baseline (Day 1) to Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    24
    29
    37
    Units: Percent change
        least squares mean (standard error)
    -47.33 ( 9.77 )
    -53.57 ( 8.25 )
    -43.33 ( 6.99 )
    -47.21 ( 6.26 )
    Statistical analysis title
    BID cohort:Placebo versus Rilzabrutinib 400 mg BID
    Statistical analysis description
    Analysis was performed by using an analysis of covariance (ANCOVA) model with the baseline EASI score, intervention group, randomization stratification of screening Immunoglobulin E (IgE) levels (< or ≥300 units international per milliliter [UI/mL]) as covariates.
    Comparison groups
    BID cohort: Placebo v BID cohort: Rilzabrutinib 400 mg BID
    Number of subjects included in analysis
    42
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.6246
    Method
    ANCOVA
    Parameter type
    Least Square Mean Difference
    Point estimate
    -6.25
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -31.26
         upper limit
    18.77
    Statistical analysis title
    TID cohort:Placebo versus Rilzabrutinib 400 mg TID
    Statistical analysis description
    Analysis was performed by using an ANCOVA model with the baseline EASI score, intervention group, randomization stratification of screening IgE levels (< or ≥300UI/mL) as covariates.
    Comparison groups
    TID cohort: Placebo v TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects included in analysis
    66
    Analysis specification
    Pre-specified
    Analysis type
    other
    P-value
    = 0.674
    Method
    ANCOVA
    Parameter type
    Least Square Mean Difference
    Point estimate
    -3.88
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -21.97
         upper limit
    14.21

    Secondary: Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16

    Close Top of page
    End point title
    Percentage of Participants With Investigator's Global Assessment (IGA) of 0 or 1 At Week 16
    End point description
    IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity. ITT population included all randomized participants analyzed according to the intervention group allocated by randomization regardless of whether the intervention was received or not.
    End point type
    Secondary
    End point timeframe
    Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Percentage of participants
        number (not applicable)
    22.2
    7.4
    12.9
    14.6
    No statistical analyses for this end point

    Secondary: Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16

    Close Top of page
    End point title
    Percentage of Participants Achieving EASI-75 (Reduction of EASI Score By ≥75% From Baseline) At Week 16
    End point description
    The EASI index is validated investigator-administered scoring system used to measure severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness [induration, papulation, edema], scratching [excoriation], and lichenification) were each assessed for severity by investigator or designee on scale of "0" (absent) through "3" (severe).In addition, area of AD involvement were assessed as percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100%. Total score=0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Participants who achieved EASI-75 were defined as participants with reduction of EASI score by ≥75% from baseline. ITT population included all randomized participants analyzed according to intervention group allocated by randomization regardless of whether intervention was received or not.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and at Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Percentage of participants
        number (not applicable)
    27.8
    29.6
    29.0
    18.8
    No statistical analyses for this end point

    Secondary: Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16

    Close Top of page
    End point title
    Percentage Of Participants With Reduction of Weekly Average of Daily Peak Pruritus Numerical Rating Scale (PP-NRS) of ≥4 Points From Baseline at Week 16
    End point description
    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. ITT population included all randomized participants analyzed according to the intervention group allocated by randomization regardless of whether the intervention was received or not.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and at Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Percentage of participants
        number (not applicable)
    11.1
    18.5
    12.9
    20.8
    No statistical analyses for this end point

    Secondary: Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period

    Close Top of page
    End point title
    Number of Participants With Weekly Average of Daily PP-NRS Reduction ≥4 From Baseline During The 16-Week Treatment Period
    End point description
    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', howwould you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. ITT population included all randomized participants analyzed according to the intervention group allocated by randomization regardless of whether the intervention was received or not.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Participants
    2
    7
    4
    13
    No statistical analyses for this end point

    Secondary: Absolute Change From Baseline to Week 16 in EASI Score

    Close Top of page
    End point title
    Absolute Change From Baseline to Week 16 in EASI Score
    End point description
    EASI index is validated investigator-administered scoring system used to measure severity of clinical signs in AD. Four AD disease characteristics (erythema, thickness [induration, papulation, edema], scratching [excoriation], and lichenification) were each assessed for severity by investigator or designee on scale of "0" (absent) through "3" (severe).In addition, area of AD involvement were assessed as a percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to score of 0 to 6. 0: 0% of BSA involvement with AD; 1: 1-9%; 2: 10-29%; 2: 30-49%; 4: 50-69%; 5: 70-89% and 6: 90-100%. Total score=0 (minimum) to 72 (maximum); higher scores indicated greater severity of AD. Baseline=Day 1 assessment value. ITT population included all randomized participants analyzed according to intervention group allocated by randomization regardless of whether intervention was received or not. Only those participants with data collected at specified timepoints are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) to Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    24
    29
    37
    Units: Scores on a scale
        least squares mean (standard error)
    -12.83 ( 2.31 )
    -14.00 ( 1.94 )
    -10.37 ( 2.48 )
    -11.34 ( 2.20 )
    No statistical analyses for this end point

    Secondary: Percentage of Participants Achieving EASI-50/90 (Reduction of EASI Score by ≥50% or ≥90% From Baseline) at Week 16

    Close Top of page
    End point title
    Percentage of Participants Achieving EASI-50/90 (Reduction of EASI Score by ≥50% or ≥90% From Baseline) at Week 16
    End point description
    EASI index is validated investigator-administered scoring system used to measure severity of clinical signs in AD. Four AD disease characteristics(erythema, thickness[induration, papulation, edema],scratching[excoriation], and lichenification)were each assessed for severity by investigator or designee on scale of "0" (absent) through "3" (severe).In addition, area of AD involvement were assessed as percentage by body area of head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6.0: 0% of BSA involvement with AD;1: 1-9%;2: 10-29%;2: 30-49%;4: 50-69%;5: 70-89% and6: 90-100%. Total score=0 (minimum) to 72 (maximum);higher scores=greater severity of AD. Participants who achieved EASI-50/90 were defined as participants with reduction of EASI score by ≥50% or ≥90% from baseline respectively. ITT population included all randomized participants analyzed according to intervention group allocated by randomization regardless of whether intervention was received or not.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and at Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Percentage of participants
    number (not applicable)
        EASI-50
    55.6
    44.4
    38.7
    29.2
        EASI-90
    16.7
    11.1
    12.9
    8.3
    No statistical analyses for this end point

    Secondary: Change From Baseline to Week 16 in Percent BSA of AD

    Close Top of page
    End point title
    Change From Baseline to Week 16 in Percent BSA of AD
    End point description
    BSA affected by AD were assessed for each section of the body (the possible highest score for each region was: head and neck [10%], trunk including genitalia [30%], upper limbs [20%], lower limbs [40%]) and were reported as a percentage of all major body sections combined. Total score ranges from 0% to 100%. The higher score indicates a worse value and a lower score indicates a better value. Baseline was defined as the Day 1 assessment value. ITT population included all randomized participants analyzed according to the intervention group allocated by randomization regardless of whether the intervention was received or not. Only those participants with data collected at specified timepoints are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) to Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    14
    20
    29
    37
    Units: Percent of body surface area
        least squares mean (standard error)
    -10.45 ( 4.37 )
    -15.30 ( 3.61 )
    -7.35 ( 3.38 )
    -11.80 ( 3.08 )
    No statistical analyses for this end point

    Secondary: Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS

    Close Top of page
    End point title
    Absolute Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS
    End point description
    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value. ITT population=all randomized participants analyzed according to intervention group allocated by randomization regardless of whether intervention was received or not. Only those participants with data collected at specified timepoints are reported.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) to Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    16
    23
    26
    36
    Units: Scores on a scale
        least squares mean (standard error)
    -1.60 ( 0.66 )
    -3.11 ( 0.52 )
    -0.83 ( 0.51 )
    -2.07 ( 0.43 )
    No statistical analyses for this end point

    Secondary: Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS

    Close Top of page
    End point title
    Percent Change From Baseline to Week 16 in Weekly Average of Daily PP-NRS
    End point description
    The PP-NRS is a simple assessment tool that participants used to report the intensity of their pruritus (itch) during a daily recall period. Participants were asked to rate their worst itch on a 0 (no itch) to 10 (worst itch imaginable) NRS by answering the following question: For itch intensity, "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". The total score on the scale ranged from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicated worse symptoms. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score. Baseline was defined as the Day 1 assessment value. ITT population=all randomized participants analyzed according to intervention group allocated by randomization regardless of whether intervention was received or not. Only those participants with data collected at specified timepoints are reported
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) to Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    16
    23
    26
    36
    Units: Percent change
        least squares mean (standard error)
    -21.55 ( 8.37 )
    -43.53 ( 6.80 )
    -10.36 ( 7.19 )
    -30.13 ( 6.08 )
    No statistical analyses for this end point

    Secondary: Percentage of Participants Achieving IGA*BSA-50/75/90 (Reduction of IGA*BSA by ≥50% or 75% or 90% From Baseline) At Week 16

    Close Top of page
    End point title
    Percentage of Participants Achieving IGA*BSA-50/75/90 (Reduction of IGA*BSA by ≥50% or 75% or 90% From Baseline) At Week 16
    End point description
    IGA is a static 5-point measure of disease severity based on an overall assessment of the skin lesions on a 5-point scale (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, 4 = severe disease). Higher score indicated higher severity. Participants who achieved IGA*BSA-50-75-90 were defined as participants with reduction of IGA*BSA by ≥50% or 75% or 90% from baseline. ITT population included all randomized participants analyzed according to the intervention group allocated by randomization regardless of whether the intervention was received or not.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) and at Week 16
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Percentage of participants
    number (not applicable)
        IGA*BSA-50
    38.9
    40.7
    38.7
    29.2
        IGA*BSA-75
    22.2
    25.9
    22.6
    18.8
        IGA*BSA-90
    5.6
    18.5
    9.7
    10.4
    No statistical analyses for this end point

    Secondary: Number Of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and Study intervention Discontinuation

    Close Top of page
    End point title
    Number Of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs) and Study intervention Discontinuation
    End point description
    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. TEAEs were defined as AEs that developed, worsened or became serious during treatment-emergent period. SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to Sponsor’s product or program, for which ongoing monitoring and immediate notification by investigator to Sponsor was required. Safety population included all randomized participants who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.
    End point type
    Secondary
    End point timeframe
    Baseline (Day 1) to 16 weeks
    End point values
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Number of subjects analysed
    18
    27
    31
    48
    Units: Participants
        TEAEs
    10
    15
    19
    38
        TESAEs
    0
    0
    1
    1
        AESI
    3
    0
    2
    0
        TEAE leading to study intervention discontinuation
    0
    2
    2
    9
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    TEAEs were collected from Baseline (Day 1) to 16 weeks. All-cause mortality (Deaths) was collected throughout the study, approximately 97 weeks.
    Adverse event reporting additional description
    Analysis was performed on safety population.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    BID cohort: Placebo
    Reporting group description
    Participants received placebo matched to rilzabrutinib orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Reporting group title
    BID cohort: Rilzabrutinib 400 mg BID
    Reporting group description
    Participants received rilzabrutinib 400 mg orally BID from Day 1 up to Week 16. Consecutive doses were ideally administered 12 hours apart (and not less than 8 hours apart).

    Reporting group title
    TID cohort: Placebo
    Reporting group description
    Participants received placebo matched to rilzabrutinib orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Reporting group title
    TID cohort: Rilzabrutinib 400 mg TID
    Reporting group description
    Participants received rilzabrutinib 400 mg orally TID from Day 1 up to Week 16. Consecutive doses were ideally administered at least 6 hours apart (and not less than 4 hours apart).

    Serious adverse events
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    1 / 48 (2.08%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Cutaneous T-Cell Lymphoma
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Abscess Limb
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    BID cohort: Placebo BID cohort: Rilzabrutinib 400 mg BID TID cohort: Placebo TID cohort: Rilzabrutinib 400 mg TID
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    10 / 18 (55.56%)
    15 / 27 (55.56%)
    19 / 31 (61.29%)
    38 / 48 (79.17%)
    Vascular disorders
    Hot Flush
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    1 / 31 (3.23%)
    1 / 48 (2.08%)
         occurrences all number
    0
    1
    1
    1
    Influenza Like Illness
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Oedema
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Pyrexia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Reproductive system and breast disorders
    Menstruation Delayed
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Respiratory, thoracic and mediastinal disorders
    Oropharyngeal Pain
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    1 / 48 (2.08%)
         occurrences all number
    1
    0
    1
    1
    Epistaxis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Dyspnoea
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 27 (7.41%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    2
    0
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Cough
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Psychiatric disorders
    Stress
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Insomnia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Anxiety
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Investigations
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    1
    0
    0
    1
    Alanine Aminotransferase Increased
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    1
    0
    0
    1
    Blood Creatine Phosphokinase Increased
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    2 / 31 (6.45%)
    1 / 48 (2.08%)
         occurrences all number
    0
    1
    2
    1
    Activated Partial Thromboplastin Time Prolonged
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    1 / 31 (3.23%)
    2 / 48 (4.17%)
         occurrences all number
    0
    1
    1
    2
    Weight Decreased
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    1
    0
    1
    Transaminases Increased
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    1
    0
    1
    Body Temperature Increased
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Blood Pressure Increased
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Injury, poisoning and procedural complications
    Eyelid Injury
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Ligament Sprain
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Limb Crushing Injury
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Stab Wound
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Cardiac disorders
    Coronary Artery Stenosis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    1
    0
    1
    Coronary Artery Disease
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Supraventricular Tachycardia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Nervous system disorders
    Hyperaesthesia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Headache
         subjects affected / exposed
    1 / 18 (5.56%)
    2 / 27 (7.41%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    1
    2
    1
    0
    Dysaesthesia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    2
    0
    0
    Tremor
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Blood and lymphatic system disorders
    Spontaneous Haematoma
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Lymphopenia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Deficiency Anaemia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Anaemia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Eye disorders
    Swelling Of Eyelid
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Conjunctivitis Allergic
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    1
    0
    0
    0
    Cataract
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Blepharitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Gastrointestinal disorders
    Abdominal Pain
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    3 / 48 (6.25%)
         occurrences all number
    0
    0
    0
    3
    Abdominal Distension
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Abdominal Discomfort
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Abdominal Pain Lower
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Constipation
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Diarrhoea
         subjects affected / exposed
    0 / 18 (0.00%)
    4 / 27 (14.81%)
    0 / 31 (0.00%)
    10 / 48 (20.83%)
         occurrences all number
    0
    7
    0
    10
    Dyspepsia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Flatulence
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Frequent Bowel Movements
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Vomiting
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Nausea
         subjects affected / exposed
    0 / 18 (0.00%)
    8 / 27 (29.63%)
    1 / 31 (3.23%)
    15 / 48 (31.25%)
         occurrences all number
    0
    8
    1
    16
    Haemorrhoidal Haemorrhage
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Gastrooesophageal Reflux Disease
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Abdominal Pain Upper
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Skin and subcutaneous tissue disorders
    Chronic Spontaneous Urticaria
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Alopecia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Acne
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    3 / 31 (9.68%)
    0 / 48 (0.00%)
         occurrences all number
    1
    0
    3
    0
    Dermatitis Atopic
         subjects affected / exposed
    3 / 18 (16.67%)
    4 / 27 (14.81%)
    9 / 31 (29.03%)
    15 / 48 (31.25%)
         occurrences all number
    3
    7
    13
    15
    Hand Dermatitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Hyperhidrosis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Livedo Reticularis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Sensitive Skin
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    4 / 48 (8.33%)
         occurrences all number
    0
    0
    0
    4
    Arthropathy
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Back Pain
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Bursitis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Myalgia
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    1
    0
    0
    0
    Infections and infestations
    Acute Sinusitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Covid-19
         subjects affected / exposed
    2 / 18 (11.11%)
    0 / 27 (0.00%)
    2 / 31 (6.45%)
    0 / 48 (0.00%)
         occurrences all number
    2
    0
    2
    0
    Eczema Impetiginous
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Pustule
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Conjunctivitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Cellulitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Eczema Infected
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Folliculitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Gastroenteritis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Gastroenteritis Viral
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    1
    0
    0
    0
    Gastrointestinal Viral Infection
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Impetigo
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Influenza
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Laryngitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Nasopharyngitis
         subjects affected / exposed
    0 / 18 (0.00%)
    2 / 27 (7.41%)
    2 / 31 (6.45%)
    3 / 48 (6.25%)
         occurrences all number
    0
    2
    2
    3
    Oral Herpes
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Pulpitis Dental
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Cystitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Skin Bacterial Infection
         subjects affected / exposed
    1 / 18 (5.56%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    1
    0
    0
    0
    Sinusitis
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Rhinolaryngitis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Rash Pustular
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Staphylococcal Skin Infection
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Vulvovaginal Candidiasis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Viral Upper Respiratory Tract Infection
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    2 / 48 (4.17%)
         occurrences all number
    0
    0
    0
    2
    Urinary Tract Infection Bacterial
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    2 / 48 (4.17%)
         occurrences all number
    0
    0
    0
    2
    Upper Respiratory Tract Infection Bacterial
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Upper Respiratory Tract Infection
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Tinea Pedis
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Systemic Viral Infection
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    1 / 31 (3.23%)
    0 / 48 (0.00%)
         occurrences all number
    0
    0
    1
    0
    Metabolism and nutrition disorders
    Decreased Appetite
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Food Aversion
         subjects affected / exposed
    0 / 18 (0.00%)
    0 / 27 (0.00%)
    0 / 31 (0.00%)
    1 / 48 (2.08%)
         occurrences all number
    0
    0
    0
    1
    Hypercholesterolaemia
         subjects affected / exposed
    0 / 18 (0.00%)
    1 / 27 (3.70%)
    0 / 31 (0.00%)
    0 / 48 (0.00%)
         occurrences all number
    0
    1
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    08 Jul 2021
    To incorporate feedback from health authorities as well as other clarifications and corrections deemed necessary by the Sponsor. Correction and clarification were done in the schedule of activities and inclusion criteria. Consistency was provided in Pregnancy section. In addition, other minor editorial changes (e.g., grammatical and minor typographical error corrections) were implemented throughout the protocol.
    03 Jan 2022
    The main reason was to evaluate the efficacy and safety of two dose regimen of rilzabrutinib, the current dose regimen of 400 mg BID and an additional higher regimen of 400 mg TID in two staggered double-blind cohorts for a total number of 120 participants split as follows: The total number of participants in the BID cohort was reduced from 70 to 50 (n=30 rilzabrutinib / 20 matching placebo); The total number of participants in the TID cohort is 70 (n=42 rilzabrutinib / 28 matching placebo). Bruton’s tyrosine kinase (BTK) appeared as an attractive drug target in AD by inhibiting the dysregulated signaling and activation of the pathogenic cells B-cells, mast cells and basophils implicated in skin inflammation suggesting the presence of both Type 1 and Type 2 inflammation as per the Gell and Coombs classification (Type 1 being an immediate hypersensitivity mediated by IgE and Type 2b being mediated by IgG autoantibody). The basophil histamine release assay (BHRA) had been used in assessing endotypes of chronic spontaneous urticaria. Those with BHRA- results were classified as Type 1 (immediate hypersensitivity mediated by IgE) while those with BHRA+ results were classified as Type 2b (mediated by IgG autoantibody). This endotype classification system had been demonstrated to contribute to clinical responses to BTK inhibitors. BHRA had not been studied extensively in AD. Thus, determining the BHRA status at baseline and end of study would provide epidemiology of BHRA classification in AD and assess if a given endotype had a better response to BTK inhibitor or not. In addition, clarifications and corrections had been made based on feedback from study sites. In addition, other minor editorial changes were implemented throughout the protocol. Administrative changes in the cover page were done. Clarification was provided in schedule of activities, study intervention(s) and concomitant therapy, eligibility criteria. Template language update was made.
    24 Aug 2022
    Inclusion and exclusion criteria were updated. In addition, clarifications and corrections deemed necessary by Sponsor were implemented. Administrative change to comply with Sanofi standard format was added. Clarification and accuracy in synopsis, schema, overall design, population for analysis, schedule of activities, study intervention compliance, concomitant therapy was provided. Updated information with the current investigator brochure. Changes were made for clarification in Clinical Safety laboratory assessments, AESI and exploratory endpoint.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 15:08:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA